e-therapeutics to Present Preclinical Data on ETX-148 at EAHAD 2025

**Summary of e-therapeutics' Presentation at EAHAD 2025**

On February 7, 2025, e-therapeutics plc will present significant preclinical data on its innovative treatment ETX-148 aimed at addressing bleeding disorders, specifically in models of haemophilia A and B. This presentation will be part of the Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) taking place in London from February 4-7, 2025. ETX-148, currently undergoing IND-enabling studies, is set for an Investigational New Drug (IND) submission in 2026.

The presentation, titled "Efficacy and Safety of ETX-148 in Murine Models of Haemophilia A and B," will highlight the therapeutic potential of the drug, showcasing its preclinical results that underscore both efficacy and safety in animal models, suggesting promising implications for future human applications.

e-therapeutics plc is at the forefront of drug discovery, uniquely integrating computational power with biological data to develop life-changing RNA interference (RNAi) therapies. Their proprietary platform, GalOmic™, specializes in generating effective small interfering RNA (siRNA) therapeutics designed to target and silence novel genes, particularly in liver cells. Complementing this is the HepNet™ computational platform, which accelerates drug development by offering insights and extensive data on hepatocyte biology.

With a focus on unmet medical needs, e-therapeutics is actively progressing several RNAi candidates in various therapeutic areas, including metabolic disorders, visual impairments, and cardiovascular diseases. Other candidates complete with positive proof-of-concept findings are ETX-312 for metabolic dysfunction-associated steatohepatitis (MASH) and ETX-407 for dry age-related macular degeneration (dry AMD). The event at EAHAD 2025 will solidify e-therapeutics' commitment to pioneering advancements in RNAi therapies.

As e-therapeutics plc prepares to present new preclinical data on ETX-148 at the EAHAD Congress, investors and market analysts should take a closer look at the implications of this development. ETX-148 is positioned to address significant unmet needs in the treatment of bleeding disorders, specifically hemophilia A and B, which could potentially attract substantial interest from both the medical community and pharmaceutical investors.

The integration of AI-driven platforms like HepNet™ and the proprietary GalOmic™ RNAi technology set ETX apart in a competitive landscape. These platforms enhance the speed and efficacy of drug development by facilitating the identification of novel gene targets and the design of effective siRNA therapeutics. Notably, the company has already established collaborations with reputable biopharma firms, which validates its innovative approach and strengthens its portfolio.

With an Investigational New Drug (IND) submission anticipated in 2026, the upcoming data presentation will be critical in gauging investor sentiment. Success in these murine models could bolster ETX’s position in the market and increase the stock's value ahead of clinical trials. Given the historical challenges and costs associated with drug development in this space, positive results could lead to accelerated interest and potentially favorable partnerships with larger pharmaceutical companies looking to diversify their portfolios.

Investors should closely monitor the outcomes of the EAHAD presentation on February 7, 2025, particularly the details around the efficacy and safety profile of ETX-148. This event presents an opportunity for e-therapeutics to secure a stronger foothold in the RNAi therapeutics market, especially in the context of bleeding disorders, where demand for effective treatment options continues to rise. Therefore, a cautious but optimistic outlook on ETX shares is advised, with a watchful eye on the market's response post-presentation.